Area of research
Virology · Infectious Diseases
Research interest
Research interests include HIV Research and Treatment, HIV/AIDS drug development and treatment, Immune Cell Function and Interaction, and HIV/AIDS Research and Interventions.
Structural and genetic basis of HIV-1 envelope V2 apex recognition by rhesus broadly neutralizing antibodies
Potent and broad HIV-1 neutralization in fusion peptide-primed SHIV-infected macaques
Neutralizing antibodies evolve to exploit vulnerable sites in the HCV envelope glycoprotein E2 and mediate spontaneous clearance of infection
Intradermal but not intramuscular modified vaccinia Ankara immunizations protect against intravaginal tier2 simian-human immunodeficiency virus challenges in female macaques
Author Correction: Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies
Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies
Heightened resistance to host type 1 interferons characterizes HIV-1 at transmission and after antiretroviral therapy interruption
Predictors of Nonseroconversion after SARS-CoV-2 Infection
The C3/465 glycan hole cluster in BG505 HIV-1 envelope is the major neutralizing target involved in preventing mucosal SHIV infection
Dynamics and origin of rebound viremia in SHIV-infected infant macaques following interruption of long-term ART
T cell-inducing vaccine durably prevents mucosal SHIV infection even with lower neutralizing antibody titers
Recapitulation of HIV-1 Env-antibody coevolution in macaques leading to neutralization breadth
SMAC Mimetic Plus Triple-Combination Bispecific HIVxCD3 Retargeting Molecules in SHIV.C.CH505-Infected, Antiretroviral Therapy-Suppressed Rhesus Macaques
Simian-Human Immunodeficiency Virus SHIV.C.CH505 Persistence in ART-Suppressed Infant Macaques Is Characterized by Elevated SHIV RNA in the Gut and a High Abundance of Intact SHIV DNA in Naive CD4 <sup>+</sup> T Cells
CD4 receptor diversity in chimpanzees protects against SIV infection
Simian-Human Immunodeficiency Virus SHIV.CH505 Infection of Rhesus Macaques Results in Persistent Viral Replication and Induces Intestinal Immunopathology
Rational design and in vivo selection of SHIVs encoding transmitted/founder subtype C HIV-1 envelopes
Vaccine-Induced Protection from Homologous Tier 2 SHIV Challenge in Nonhuman Primates Depends on Serum-Neutralizing Antibody Titers
Tracking HIV-1 recombination to resolve its contribution to HIV-1 evolution in natural infection
Vaccine-induced protection from homologous Tier 2 simian-human immunodeficiency virus challenge in nonhuman primates
Staged induction of HIV-1 glycan–dependent broadly neutralizing antibodies
Broadly neutralizing antibodies with few somatic mutations and hepatitis C virus clearance
Maturation Pathway from Germline to Broad HIV-1 Neutralizer of a CD4-Mimic Antibody
Envelope residue 375 substitutions in simian–human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques
HIV-1 Vpu Mediates HLA-C Downregulation
Neutralization Takes Precedence Over IgG or IgA Isotype-related Functions in Mucosal HIV-1 Antibody-mediated Protection
Collapse of Cytolytic Potential in SIV-Specific CD8+ T Cells Following Acute SIV Infection in Rhesus Macaques
Derivation and Characterization of Pathogenic Transmitted/Founder Molecular Clones from Simian Immunodeficiency Virus SIVsmE660 and SIVmac251 following Mucosal Infection
Transmitted Virus Fitness and Host T Cell Responses Collectively Define Divergent Infection Outcomes in Two HIV-1 Recipients
Neutralization Properties of Simian Immunodeficiency Viruses Infecting Chimpanzees and Gorillas